EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

Colorectal cancer screening: An update to the American Cancer Society guideline, 2026

Andrew M D Wolf iD, Richard M Hoffman iD, Louise C Walter iD, Charnita Zeigler-Johnson iD, Timothy R Church iD, Carmen E Guerra iD, Elena B Elkin iD, Ruth Etzioni iD, Abbe Herzig iD, Kevin C Oeffinger iD, Rebecca B Perkins iD, Sana Raoof iD und 5 weitere

CA: A Cancer Journal for Clinicians · 2026-05 · 76 (3)

DOI: 10.3322/caac.70083 ↗

Kurz gefasst

Leitlinie in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 27.05.2026. Verfasst von Andrew M D Wolf und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of Virginia School of Medicine, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Early Detection of Cancer. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is a leading cause of cancer incidence and mortality in the United States, with rates recently increasing among adults younger than 65 years. In 2018, the American Cancer Society (ACS) lowered the recommended age to initiate screening for average‐risk adults to age 45 years. Since then, new molecular‐based screening tests—a multitarget stool RNA test (mt‐sRNA), a next‐generation mt‐sDNA test, and a blood‐based cell‐free DNA assay—have received regulatory approval for CRC screening. For this update, the ACS Guideline Development Group commissioned a targeted, systematic evidence review evaluating diagnostic performance and published modeling studies to judge the potential impact of these tests on CRC incidence and mortality. The ACS reaffirms the recommendation that average‐risk adults should initiate CRC screening at age 45 years and continue through age 75 years for those with a life expectancy greater than 10 years. Consistent with prior guidelines, the ACS emphasizes that offering multiple, recommended screening options supports informed patient choice and may improve participation, because the most effective screening test is the one that the patient completes. The next‐generation mt‐sDNA test, which is an updated version of an already recommended mt‐sDNA test, and the mt‐sRNA test demonstrated high sensitivity for CRC and moderate sensitivity for advanced precancerous lesions and are recommended, along with annual high‐sensitivity fecal immunochemical and high‐sensitivity guaiac‐based fecal occult blood tests, as preferred stool‐based screening options at 3‐year intervals. Compared with established stool‐based tests, blood‐based tests demonstrated lower sensitivity for both advanced precancerous lesions and stage I cancers, with modeling studies predicting less effectiveness in reducing CRC incidence and mortality. At this time, blood‐based tests should be recommended only to individuals who decline or do not complete preferred screening tests. Ongoing evaluation of adherence, real‐world implementation, and clinical outcomes will inform future updates for these new tests. For screening to be effective, a positive result on any noncolonoscopy screening test requires timely follow‐up with colonoscopy, preferably within 6 months, to complete the screening process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsEarly Detection of CancerHumansUnited StatesAmerican Cancer SocietyFecesMiddle AgedMass ScreeningOccult BloodAgedBiomarkers, TumorPractice Guidelines as Topic

Stichwörter der Autor:innen

blood‐based screening testscolorectal cancerepidemiologymultitarget stool RNA (mt‐sRNA)public healthscreening and early detection

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
  • University of California, San Francisco and the San Francisco Veterans Affairs Health Care System, San Francisco, California, USA.
  • Cancer Prevention and Control, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
  • University of Minnesota School of Public Health, Minneapolis, Minnesota, USA.
  • Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Andrew M D Wolf, Richard M Hoffman, Louise C Walter, Charnita Zeigler-Johnson, Timothy R Church, Carmen E Guerra, Elena B Elkin, Ruth Etzioni, Abbe Herzig, Kevin C Oeffinger, Rebecca B Perkins, Sana Raoof, Ya-Chen Tina Shih, Steven J Skates, Tyler B Kratzer, Deana Manassaram-Baptiste, Robert A Smith

Zitieren

APA

Wolf, A. M. D., Hoffman, R. M., Walter, L. C., Zeigler-Johnson, C., Church, T. R., Guerra, C. E., Elkin, E. B., Etzioni, R., Herzig, A., Oeffinger, K. C., Perkins, R. B., Raoof, S., Tina Shih, Y. C., Skates, S. J., Kratzer, T. B., Manassaram-Baptiste, D., & Smith, R. A. (2026). Colorectal cancer screening: An update to the American Cancer Society guideline, 2026. CA: A Cancer Journal for Clinicians, 76(3). https://doi.org/10.3322/caac.70083

Vancouver

Wolf AMD, Hoffman RM, Walter LC, Zeigler-Johnson C, Church TR, Guerra CE, et al. Colorectal cancer screening: An update to the American Cancer Society guideline, 2026. CA: A Cancer Journal for Clinicians. 2026;76(3). doi:10.3322/caac.70083

BibTeX
@article{Wolf2026,
  author = {Wolf, Andrew M D and Hoffman, Richard M and Walter, Louise C and Zeigler-Johnson, Charnita and Church, Timothy R and Guerra, Carmen E and Elkin, Elena B and Etzioni, Ruth and Herzig, Abbe and Oeffinger, Kevin C and Perkins, Rebecca B and Raoof, Sana and Tina Shih, Ya-Chen and Skates, Steven J and Kratzer, Tyler B and Manassaram-Baptiste, Deana and Smith, Robert A},
  title = {Colorectal cancer screening: An update to the American Cancer Society guideline, 2026},
  journal = {CA: A Cancer Journal for Clinicians},
  year = {2026},
  volume = {76},
  number = {3},
  doi = {10.3322/caac.70083}
}
Kostenlos starten →